Hao Zeng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3001842/publications.pdf Version: 2024-02-01



HAO ZENO

#	Article	IF	CITATIONS
1	Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics, 2021, 11, 2098-2107.	4.6	75
2	ls there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?. Prostate, 2015, 75, 225-232.	1.2	58
3	Survival and prognostic analysis of preoperative inflammatory markers in patients undergoing surgical resection for laryngeal squamous cell carcinoma. BMC Cancer, 2018, 18, 816.	1.1	57
4	Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1734-1743.	3.2	54
5	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer, 2019, 19, 360.	1.1	52
6	The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. Prostate, 2015, 75, 1247-1254.	1.2	49
7	Stemness Related Genes Revealed by Network Analysis Associated With Tumor Immune Microenvironment and the Clinical Outcome in Lung Adenocarcinoma. Frontiers in Genetics, 2020, 11, 549213.	1.1	47
8	Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. Journal of Proteomics, 2016, 132, 85-92.	1.2	45
9	Chronic stress promotes EMT-mediated metastasis through activation of STAT3 signaling pathway by miR-337-3p in breast cancer. Cell Death and Disease, 2020, 11, 761.	2.7	45
10	Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer. Scientific Reports, 2015, 5, 7713.	1.6	41
11	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nature Communications, 2021, 12, 5262.	5.8	40
12	Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-11±. Oncotarget, 2017, 8, 83523-83538.	0.8	40
13	Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. Scientific Reports, 2016, 6, 23503.	1.6	37
14	Integrated Analysis of mRNA-seq and miRNA-seq to Identify c-MYC, YAP1 and miR-3960 as Major Players in the Anticancer Effects of Caffeic Acid Phenethyl Ester in Human Small Cell Lung Cancer Cell Line. Current Gene Therapy, 2020, 20, 15-24.	0.9	34
15	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2020, 18, 42.	0.8	32
16	Evaluation of CT-based radiomics signature and nomogram as prognostic markers in patients with laryngeal squamous cell carcinoma. Cancer Imaging, 2020, 20, 28.	1.2	31
17	The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Oncotarget, 2017, 8, 55374-55383.	0.8	30
18	Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma. Journal of Cancer, 2018, 9, 3303-3310.	1.2	28

#	Article	IF	CITATIONS
19	Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Frontiers in Physiology, 2019, 10, 843.	1.3	25
20	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 935-944.	1.2	24
21	Comparison of Diagnostic Performance of Five Different Ultrasound TI-RADS Classification Guidelines for Thyroid Nodules. Frontiers in Oncology, 2020, 10, 598225.	1.3	24
22	Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer. Gynecologic Oncology, 2021, 163, 171-180.	0.6	23
23	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castrationâ€resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a firstâ€line therapy. Prostate, 2019, 79, 1553-1562.	1.2	22
24	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. BMC Cancer, 2019, 19, 49.	1.1	21
25	Apigenin inhibits the growth of colorectal cancer through down-regulation of E2F1/3 by miRNA-215-5p. Phytomedicine, 2021, 89, 153603.	2.3	21
26	Prophylactic Antibiotics in Prostate Biopsy: A Meta-Analysis Based on Randomized Controlled Trials. Surgical Infections, 2015, 16, 733-747.	0.7	20
27	The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer. Prostate, 2016, 76, 823-833.	1.2	20
28	Laparoscopic resection of a huge mature cystic teratoma of the right adrenal gland through retroperitoneal approach: a case report and literature review. World Journal of Surgical Oncology, 2015, 13, 318.	0.8	19
29	Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Scientific Reports, 2019, 9, 17985.	1.6	19
30	Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma. Aging, 2021, 13, 9960-9975.	1.4	19
31	The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with De Novo Metastatic Prostate Cancer. Journal of Urology, 2019, 201, 759-768.	0.2	19
32	Multifocal Brain Metastases in Clear Cell Renal Cell Carcinoma with Complete Response to Sunitinib. Urologia Internationalis, 2009, 83, 482-485.	0.6	18
33	Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. Frontiers in Oncology, 2020, 10, 519388.	1.3	18
34	Exploration and validation of the effects of robust co-expressed immune-related genes on immune infiltration patterns and prognosis in laryngeal cancer. International Immunopharmacology, 2020, 85, 106622.	1.7	18
35	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU International, 2022, 129, 345-355.	1.3	18
36	Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials. Clinical Drug Investigation, 2019, 39, 27-43.	1.1	17

#	Article	IF	CITATIONS
37	Survival Prediction in Gallbladder Cancer Using CT Based Machine Learning. Frontiers in Oncology, 2020, 10, 604288.	1.3	17
38	SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 3871-81.	0.5	17
39	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgenâ€deprivation therapy in highâ€risk prostate cancer following radical prostatectomy. Prostate, 2017, 77, 1279-1287.	1.2	16
40	Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma. International Journal of Oncology, 2018, 54, 348-360.	1.4	16
41	Novel nomograms for castrationâ€resistant prostate cancer and survival outcome in patients with <i>de novo</i> bone metastatic prostate cancer. BJU International, 2018, 122, 994-1002.	1.3	16
42	The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma. Neoplasia, 2019, 21, 921-931.	2.3	16
43	Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Oncotarget, 2017, 8, 10145-10160.	0.8	16
44	Construction of Prostateâ€Specific Expressed Recombinant Plasmids With High Transcriptional Activity of Prostateâ€Specific Membrane Antigen (PSMA) Promoter/Enhancer. Journal of Andrology, 2005, 26, 215-221.	2.0	15
45	Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases. Journal of Clinical Pathology, 2019, 72, 748-754.	1.0	15
46	Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castrationâ€resistant prostate cancer patients. Prostate, 2021, 81, 721-727.	1.2	15
47	Recombinant Adenovirus Mediated Prostate-Specific Enzyme Pro-Drug Gene Therapy Regulated by Prostate-Specific Membrane Antigen (PSMA) Enhancer/Promoter. Journal of Andrology, 2007, 28, 827-835.	2.0	14
48	The clinical significance of perineural invasion in patients with de novo metastatic prostate cancer. Andrology, 2019, 7, 184-192.	1.9	14
49	Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. Cancer Medicine, 2020, 9, 959-970.	1.3	14
50	Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis. Journal of Clinical Pathology, 2021, 74, 171-176.	1.0	14
51	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer, 2021, 160, 50-58.	0.9	14
52	The AKR1C3/ARâ€V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression. Journal of Cellular and Molecular Medicine, 2020, 24, 12032-12043.	1.6	13
53	Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer. Asian Journal of Andrology, 2020, 22, 519.	0.8	13
54	Transcriptional regulation of BNIP3 by Sp3 in prostate cancer. Prostate, 2015, 75, 1556-1567.	1.2	12

#	Article	IF	CITATIONS
55	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. BJU International, 2020, 125, 541-552.	1.3	12
56	The roles of prostateâ€specific antigen (PSA) density, prostate volume, and their zoneâ€adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0Âng/ <scp>mL</scp> . Andrology, 2017, 5, 548-555.	1.9	11
57	What kind of patients with castration-naÃ ⁻ ve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 505-517.	0.8	11
58	<p>Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study</p> . OncoTargets and Therapy, 2019, Volume 12, 3859-3868.	1.0	11
59	Histopathological image and gene expression pattern analysis for predicting molecular features and prognosis of head and neck squamous cell carcinoma. Cancer Medicine, 2021, 10, 4615-4628.	1.3	11
60	Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study. Asian Journal of Andrology, 2019, 21, 612.	0.8	11
61	Simultaneous ureteroscopic lithotripsy and contralateral percutaneous nephrolithotomy for ureteral calculi combined with renal staghorn calculi. International Journal of Urology, 2015, 22, 943-948.	0.5	10
62	Exploration of an Integrative Prognostic Model of Radiogenomics Features With Underlying Gene Expression Patterns in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 640881.	1.3	10
63	Facial Expression Recognition With Machine Learning and Assessment of Distress in Patients With Cancer. Oncology Nursing Forum, 2021, 48, 81-93.	0.5	10
64	Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis. International Journal of Surgery, 2018, 52, 214-220.	1.1	9
65	Phase I clinical trial of <scp>HC</scp> â€1119: A deuterated form of enzalutamide. International Journal of Cancer, 2021, 149, 1473-1482.	2.3	9
66	The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard firstâ€line therapy for patients with metastatic castrationâ€resistant prostate cancer. Prostate, 2021, 81, 1191-1201.	1.2	9
67	Integrative Analysis of Histopathological Images and Genomic Data in Colon Adenocarcinoma. Frontiers in Oncology, 2021, 11, 636451.	1.3	9
68	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. Frontiers in Pharmacology, 2021, 12, 789319.	1.6	9
69	Quantitative proteomics of CSF reveals potential predicted biomarkers for extranodal NK-/T-cell lymphoma of nasal-type with ethmoidal sinus metastasis. Life Sciences, 2018, 198, 94-98.	2.0	8
70	New practical methods to obtain crucial data in performing diagnostic metaâ€analysis of the published literature. Journal of Evidence-Based Medicine, 2018, 11, 56-63.	2.4	8
71	Transcriptoâ€based network analysis reveals a model of gene activation in tongue squamous cell carcinomas. Head and Neck, 2019, 41, 4098-4110.	0.9	8
72	HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC. BMC Cancer, 2020, 20, 796.	1.1	8

#	Article	IF	CITATIONS
73	Clinicopathological and radiological significance of the collateral vessels of renal cell carcinoma on preoperative computed tomography. Scientific Reports, 2021, 11, 5187.	1.6	8
74	Exosomal TUBB3 mRNA expression of metastatic castrationâ€resistant prostate cancer patients: Association with patient outcome under abiraterone. Cancer Medicine, 2021, 10, 6282-6290.	1.3	8
75	Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?. Prostate, 2019, 79, 1673-1682.	1.2	7
76	Machine learning analysis of DNA methylation in a hypoxia-immune model of oral squamous cell carcinoma. International Immunopharmacology, 2020, 89, 107098.	1.7	7
77	Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib. Lung Cancer, 2020, 146, 355-357.	0.9	7
78	Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone. BMC Cancer, 2021, 21, 919.	1.1	7
79	Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 588299.	1.8	7
80	Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study. Asian Journal of Andrology, 2018, 20, 545.	0.8	7
81	Nomogram based on pre-treatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma. Cancer Biomarkers, 2020, 29, 151-161.	0.8	6
82	Histopathological Images and Multi-Omics Integration Predict Molecular Characteristics and Survival in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 720110.	1.8	6
83	Integrative Models of Histopathological Image Features and Omics Data Predict Survival in Head and Neck Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2020, 8, 553099.	1.8	5
84	Urogenital System Damaging Manifestations of 3 Human Infected Coronaviruses. Journal of Urology, 2021, 205, 671-677.	0.2	5
85	Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib. Frontiers in Oncology, 2021, 11, 722843.	1.3	5
86	Ultrasonographic Findings of Renal Cell Carcinomas Associated with Xp11.2 Translocation/TFE3 Gene Fusion. Contrast Media and Molecular Imaging, 2017, 2017, 1-5.	0.4	4
87	The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis. Radiation Oncology, 2019, 14, 197.	1.2	4
88	Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis. Frontiers in Oncology, 2020, 10, 607576.	1.3	4
89	<p>The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs</p> . Cancer Management and Research, 2020, Volume 12, 891-903.	0.9	4
90	ls Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?. Frontiers in Oncology, 2021, 11, 643051.	1.3	4

#	Article	IF	CITATIONS
91	Clinical outcomes of secondâ€line treatment following firstâ€line VEGFRâ€TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus antiâ€PDâ€1 antibody. Cancer Communications, 2021, 41, 1071-1074.	3.7	4
92	Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. Cancer Management and Research, 2021, Volume 13, 6833-6845.	0.9	4
93	Predict Lymph Node Metastasis in Penile Cancer Using Clinicopathological Factors and Nomograms. Cancer Management and Research, 2021, Volume 13, 7429-7437.	0.9	4
94	Clinical and oncologic findings of extraprostatic extension on needle biopsy in de novo metastatic prostate cancer. Asian Journal of Andrology, 2020, 22, 427.	0.8	4
95	Proteomic Analysis of Cerebrospinal Fluid From Patients With Extranodal NK-/T-Cell Lymphoma of Nasal-Type With Ethmoidal Sinus Metastasis. Frontiers in Oncology, 2019, 9, 1489.	1.3	4
96	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 5416-5432.	0.0	4
97	The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 9061-9070.	1.0	3
98	Quantitative proteomic analysis of cerebrospinal fluid from patients with diffuse large B‑cell lymphoma with central nervous system involvement: A novel approach to diagnosis. Biomedical Reports, 2019, 11, 70-78.	0.9	3
99	<p>The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study</p> . Cancer Management and Research, 2019, Volume 11, 6521-6529.	0.9	3
100	MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8. Translational Cancer Research, 2020, 9, 3507-3517.	0.4	3
101	Prognostic Values of Different Clinicopathological Factors and Predictive Models for Penile Carcinoma. Cancer Management and Research, 2021, Volume 13, 5623-5632.	0.9	3
102	A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report. Annals of Palliative Medicine, 2021, 10, 8352-8357.	0.5	3
103	Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancer. Asian Journal of Andrology, 2017, 19, 573.	0.8	3
104	Differential expressions of PD-1, PD-L1, and PD-L2 between the primary and metastatic sites in renal cell carcinoma Journal of Clinical Oncology, 2018, 36, 616-616.	0.8	3
105	Factorâ€inhibiting hypoxiaâ€inducible factor expression in patients with highâ€risk locally advanced renal cell carcinoma and its relationship with tumor progression. Kaohsiung Journal of Medical Sciences, 2014, 30, 12-19.	0.8	2
106	Intramural esophageal dissection: a rare complication of upper gastrointestinal endoscopy. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 71-72.	0.2	2
107	A rare case of renal angiomyolipoma involved both inferior vena cava and pulmonary arteries. Journal of Thoracic Disease, 2018, 10, E166-E169.	0.6	2
108	Renal Ewing sarcoma treated with apatinib. Anti-Cancer Drugs, 2018, 29, 702-704.	0.7	2

#	Article	IF	CITATIONS
109	Use of a water-cooled Nd: YAG pulsed laser in the treatment of giant gingival pyogenic granulomas during pregnancy. Journal of Stomatology, Oral and Maxillofacial Surgery, 2020, 121, 305-307.	0.5	2
110	The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. Cancer Control, 2020, 27, 107327482097714.	0.7	2
111	The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Japanese Journal of Clinical Oncology, 2020, 50, 1454-1463.	0.6	2
112	Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2021, .	0.8	2
113	Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 685047.	1.3	2
114	The effect of AKR1C3 on the switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients receiving abiraterone Journal of Clinical Oncology, 2020, 38, 133-133.	0.8	1
115	The prognostic role of IDC-P in mCRPC and its predictive value in those treated with docetaxel or abiraterone as first-line therapy Journal of Clinical Oncology, 2017, 35, e603-e603.	0.8	1
116	Is it the time to shift paradigms in castration naÃ⁻ve prostate cancer (CNPC): A meta-analysis of upfront docetaxel and abiraterone in men with CNPC Journal of Clinical Oncology, 2018, 36, 360-360.	0.8	1
117	Phase I study of HC-1119, an androgen receptor inhibitor: Results from the dose escalation and expansion cohorts Journal of Clinical Oncology, 2018, 36, e17021-e17021.	0.8	1
118	A primary rectal neoplasm with novel DDX5-TFEB fusion. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	1.4	1
119	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy Journal of Clinical Oncology, 2017, 35, e595-e595.	0.8	0
120	Angiomotin to regulate prostate cancer cell proliferation by signaling through Hippo-YAP pathway Journal of Clinical Oncology, 2017, 35, e559-e559.	0.8	0
121	Will second-line nonsteroidal antiandrogen drugs (NSAA) after the failure of bicalutamide affect the therapeutic efficacy of the sequential abiraterone treatment?. Journal of Clinical Oncology, 2018, 36, 337-337.	0.8	0
122	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer Journal of Clinical Oncology, 2018, 36, 336-336.	0.8	0
123	The prognostic value of body fat components in metastasis renal cell carcinoma patients treated with TKIs Journal of Clinical Oncology, 2020, 38, 668-668.	0.8	0
124	High-exosomal AKR1C3 mRNA expression as a marker of poor efficacy of abiraterone in metastatic PCa patients Journal of Clinical Oncology, 2020, 38, 196-196.	0.8	0
125	Occurrence of tyrosine kinase inhibitors-induced renal impairment and its predictive value for the prognosis of patients with metastatic renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 693-693.	0.8	0
126	Exosomal TUBB3 mRNA expression level to predict prognosis for abiraterone treatment in metastatic prostate patients Journal of Clinical Oncology, 2020, 38, 244-244.	0.8	0

#	Article	IF	CITATIONS
127	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis Journal of Clinical Oncology, 2020, 38, 369-369.	0.8	0
128	Genomic landscape and immune microenvironment features of FH-deficient renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 717-717.	0.8	0
129	Distinctive landscape of genetic mutation in patients with intraductal carcinoma of the prostate (IDC-P) Journal of Clinical Oncology, 2020, 38, 192-192.	0.8	0
130	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. Immunotherapy, 2022, 14, 309-320.	1.0	0
131	Identification and validation of co-expressed immune-related gene signature affecting the pattern of immune infiltrating in esophageal cancer. Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	0.6	0